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1.B-cell chronic lymphocytic leukemia (CLL) is the most prevalent B-cell malignancy in adults.  
2.Spleen tyrosine kinase (SYK) plays a pivotal role for B-lymphocyte development and maturation in B-cell receptor (BCR) signaling pathway  
3.SYK is activated by conserved tyrosine residues sequential phosphorylation. SYK phosphorylates several downstream signaling elements, such as BLNK, Vav, Btk, phospholipase Cγ2 (PLCγ2), and 
growth factor receptor binding proteins. 
4.Designing SYK inhibitors would reduce phosphorylation of SYK downstream targets and induced apoptosis in primary chronic lymphocytic leukemia cells hence represents a potential therapeutic 
target for CLL.  
5. The present study is directed towards finding novel inhibitors of SYK through ligand based virtual screening.  
  
 
                                                                  
                                      
                                                                                   
                                                                      
  
 
 
 
 
 
 
 
               
       Virtual screening (HTVS, SP and XP) 
        
    Fifteen lead molecules 
 
 
Figure1:SYK protein involved  in B- cell receptor signal-
ling Pathway 
Figure2:Human SYK protein X-ray crystal structure with 
 p5c ligand . 
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 Figure3:Comparison of XP G scores of SYK five  pub-
lished  inhibitors along  with  fifteen lead molecules 
Figure 4:Best  two leads 
Fifteen lead molecules with good binding affinity to SYK were identified and compared with binding affinities and orientations 
of five published inhibitors. 
Apigenin (-10.05 Kcal/mol) and Glafenine (-9.72 Kcal/mol) endeavored better binding affinities, hydrogen bonding network and 
Van der Waal interactions with active site residues compared to published inhibitors.Thus, Apigenin and Glafenine would be 
valuable for designing novel inhibitors against CLL, if synthesized and tested in vitro and in vivo. 
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 Figure 5:Lead ‘1’  molecule (apigenin) forming 4 Hydrogen bonds 
with SYK protein residues and least docking score-(-10.05 kcal/mol).  
Hydrogen bonds are Leu-377,Ala-451,Asp-512W-2047 
1.Apigenin (4,5,7-trihydroxyflavone), a common 
dietary flavonoid abundantly present in fruits 
and vegetables, shows promising biological ef-
fects such as prevention and therapy of prostate 
cancer, suppression of tumor genesis and angio-
genesis in melanoma1and breast, skin, and co-
lon carcinomas. 
2.Glafenine -Chemical name: Benzoic acid, 2-((7-
chloro4quinlinyamino),2,3dihydroxypropylester.
An anthranilic acid derivative with analgesic 
properties used for the relief of all types of pain. 
    Two potential inhibitors 
(Comparative analysis with published  inhibitors) 
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